Header Image

Outcome measures I

Updated hidradenitis suppurativa area and severity index (HASI):
revised tool and psychometric assessment (abstract ID 27)

Defining flare in HS: Latest results from an international Delphi study
(abstract ID 28)

Clinical response rates, placebo response rates and significantly
associated covariates are dependent upon choice of outcome measure
in hidradenitis suppurativa: A post-hoc analysis of PIONEER 1 and 2 individual patient data (abstract ID 32)

Development and validation of HSCAPS-1: a prediction model for
diagnosis of hidradenitis suppurativa over cutaneous abscess
(abstract ID 45)

Validation of EQ-5D-5L, Skindex-16 and DLQI-R in comparison with
Dermatology Life Quality Index in patients with hidradenitis suppurativa
(abstract ID 54)

Novel phenotype classification of hidradenitis suppurativa based upon
clinical, ultrasonographical and analytical parameters. Part 2
(abstract ID 81)

Earlier onset of hidradenitis suppurativa in patients with multiple
abscesses (abstract ID 93)

VitaminDand its correlation with BMI andMEDASscore in patients with
hidradenitis suppurativa – results of a unicentric cross-sectional study
(abstract ID 106)

Validation study of a new disease specific instrument to assess patient
benefit from treatment by patients with hidradenitis suppurativa – HSPBI
(abstract ID 123)

Predictive factors associated with response to adalimumab in patients
with hidradenitis suppurativa (abstract ID 125)